OR WAIT null SECS
January 14, 2025
Article
In patients with MASLD and T2D, GLP-1 RA use was linked to a 16% relative risk reduction in major adverse liver outcomes compared with SGLT2i use.
January 07, 2025
Hyperuricemia was significantly linked to dyslipidemia and hypertriglyceridemia in hospitalized patients with type 2 diabetes, which remained after adjustment.
January 06, 2025
Podcast
In this episode, hosts discuss optimizing insulin therapy for people with diabetes using AI-driven algorithms with Eran Atlas, CEO of DreaMed Diabetes.
January 05, 2025
Our Endocrinology Month in Review for December 2024 highlights recent headlines in diabetes and endocrinology and 4 new episodes of Diabetes Dialogue.
January 03, 2025
A systematic review and meta-analysis of observational real-world data finds nearly half of patients who begin a GLP-1 RA will discontinue within a year.
January 02, 2025
In this episode, hosts discuss a slight dip in US obesity rates, the use of inhaled insulin, and the benefit of mifepristone for HbA1c reduction.
January 01, 2025
A list recapping our most popular endocrinology coverage from the past year.
December 23, 2024
The FDA's approval marks the second generic approval referencing a GLP-1 receptor agonist in as many months for the agency.
December 22, 2024
In this episode, hosts discuss the efficacy of MariTide for obesity, a head-to-head comparison of semaglutide vs. tirzepatide, and concerns about GLP-1 agonist compounding.
December 20, 2024
A study finds that individuals with low or high LDL cholesterol levels face a greater cardiovascular risk than those with medium levels.
